Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Talecris’s AAT drug wins orphan designation
Through this designation, the European Medicines Agency (EMEA) will provide to Talecris ten years of market exclusivity if the product is the first to be approved for marketing
Through this designation, the European Medicines Agency (EMEA) will provide to Talecris ten years of market exclusivity if the product is the first to be approved for marketing
The new trials include the following disease indications: follicular non-Hodgkin’s lymphoma, metastatic breast cancer, metastatic sarcoma, chronic myelogenous leukemia, and non-small cell lung cancer. The new oncology clinical
The grant was based on studies submitted in response to a written request by the FDA to investigate the use of Topomax in pediatric patients aged one to
Under the terms of the amended agreement, Biosense Webster will provide Stereotaxis a total of $18 million, comprised of advances against royalties on catheter sales and deferrals of
The company said that its main focus will be to target the patients needing supplemental medical nutrition for cancer, diabetes and obesity. Paul Lisenby, CEO of XTend Medical,
A total of 34 patients have been treated in the two Phase I studies (Phase I and Phase Ib), and safety, tolerability and early activity are being evaluated
Mr Ho joins U-Systems from Metron Systems, Snoqualmie, Washington, an advanced laser scanning company which provides highly accurate 3D measurement of complex parts for the medical and aerospace
SpectraScience’s Luma cervical imaging system was developed to significantly improve the detection of high-grade precancerous cervical abnormalities that have the potential to become invasive cancer. The Luma system
Mr Farnsworth joined Bausch & Lomb in 1988 as vice president of Business development for the former international division. Mr Farnsworth holds a Bachelor of Arts degree in
The European Patent Office announced that it intends to grant a European patent covering Silence’s lead internal product candidate. This patent will give Silence broad exclusivity not only